XTX Topco Ltd Takes Position in ANI Pharmaceuticals, Inc. (NASDAQ:ANIP)

XTX Topco Ltd purchased a new stake in shares of ANI Pharmaceuticals, Inc. (NASDAQ:ANIP - Free Report) in the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm purchased 18,029 shares of the specialty pharmaceutical company's stock, valued at approximately $997,000. XTX Topco Ltd owned about 0.09% of ANI Pharmaceuticals at the end of the most recent quarter.

A number of other hedge funds have also bought and sold shares of ANIP. State Street Corp raised its holdings in shares of ANI Pharmaceuticals by 9.1% in the 3rd quarter. State Street Corp now owns 703,843 shares of the specialty pharmaceutical company's stock worth $41,991,000 after purchasing an additional 58,698 shares during the period. Global Alpha Capital Management Ltd. lifted its position in shares of ANI Pharmaceuticals by 16.4% during the 4th quarter. Global Alpha Capital Management Ltd. now owns 624,550 shares of the specialty pharmaceutical company's stock valued at $34,525,000 after buying an additional 88,100 shares during the last quarter. JPMorgan Chase & Co. grew its stake in shares of ANI Pharmaceuticals by 159.3% during the 3rd quarter. JPMorgan Chase & Co. now owns 554,835 shares of the specialty pharmaceutical company's stock worth $33,101,000 after acquiring an additional 340,854 shares during the period. William Blair Investment Management LLC grew its stake in shares of ANI Pharmaceuticals by 2.2% during the 4th quarter. William Blair Investment Management LLC now owns 485,268 shares of the specialty pharmaceutical company's stock worth $26,826,000 after acquiring an additional 10,440 shares during the period. Finally, Geode Capital Management LLC increased its holdings in ANI Pharmaceuticals by 0.9% in the 4th quarter. Geode Capital Management LLC now owns 428,999 shares of the specialty pharmaceutical company's stock worth $23,720,000 after acquiring an additional 3,774 shares during the last quarter. 76.05% of the stock is currently owned by institutional investors.

ANI Pharmaceuticals Price Performance

ANIP traded down $0.54 during trading on Monday, reaching $68.68. The stock had a trading volume of 18,370 shares, compared to its average volume of 270,468. The company has a debt-to-equity ratio of 1.52, a quick ratio of 1.97 and a current ratio of 2.74. The business has a 50-day moving average of $63.26 and a 200-day moving average of $59.46. ANI Pharmaceuticals, Inc. has a one year low of $52.50 and a one year high of $70.48. The stock has a market cap of $1.50 billion, a PE ratio of -124.86 and a beta of 0.49.

Insider Activity at ANI Pharmaceuticals

In other news, VP Meredith Cook sold 400 shares of ANI Pharmaceuticals stock in a transaction dated Monday, April 14th. The stock was sold at an average price of $68.96, for a total value of $27,584.00. Following the transaction, the vice president now owns 80,145 shares in the company, valued at approximately $5,526,799.20. The trade was a 0.50 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, SVP Krista Davis sold 1,000 shares of the stock in a transaction dated Friday, March 7th. The shares were sold at an average price of $60.86, for a total value of $60,860.00. Following the sale, the senior vice president now owns 66,525 shares of the company's stock, valued at $4,048,711.50. This represents a 1.48 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders have sold 3,200 shares of company stock valued at $197,792. Corporate insiders own 12.70% of the company's stock.

Analysts Set New Price Targets

Several equities analysts have recently weighed in on the stock. Guggenheim reiterated a "buy" rating and issued a $86.00 target price on shares of ANI Pharmaceuticals in a research note on Friday, April 11th. HC Wainwright reissued a "buy" rating and set a $94.00 target price on shares of ANI Pharmaceuticals in a report on Monday, March 17th. StockNews.com raised ANI Pharmaceuticals from a "sell" rating to a "hold" rating in a report on Wednesday, April 16th. Jefferies Financial Group started coverage on ANI Pharmaceuticals in a research note on Friday, March 14th. They set a "buy" rating and a $80.00 price objective on the stock. Finally, JPMorgan Chase & Co. began coverage on ANI Pharmaceuticals in a report on Wednesday, March 12th. They set an "overweight" rating and a $85.00 target price for the company. Two equities research analysts have rated the stock with a hold rating, seven have assigned a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat.com, ANI Pharmaceuticals presently has a consensus rating of "Moderate Buy" and an average target price of $79.75.

ANI Pharmaceuticals Profile

ANI Pharmaceuticals, Inc, a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; controlled substances; and potent products, as well as performs contract development and manufacturing of pharmaceutical products.